IP Library Granted Patent US 7,572,444
Granted Patent B2
US 7,572,444 · App. 11/303,608 · Granted Aug 11, 2009

Binding proteins specific for human matriptase

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,572,444
App. No.
11/303,608
Granted
Aug 11, 2009
Kind
B2
Abstract

Binding proteins, such as fully human monoclonal antibodies and fragments thereof, directed to the antigen Matriptase and uses of such binding proteins are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising heavy and light chain immunoglobulin molecules capable of binding to Matriptase are also disclosed. The invention also discloses cell lines expressing such immunoglobulin molecules and monoclonal antibodies to Matriptase. The antibodies can be used to detect, prevent, and treat diseases such as cancer.

Claims (19)

1. A monoclonal antibody or binding fragment thereof that specifically binds to and neutralizes Matriptase catalytic domain; wherein said monoclonal antibody comprises:

a) a heavy chain polypeptide comprising the sequence set forth in SEQ ID NO:4 and a light chain polypeptide comprising the sequence set forth in SEQ ID NO:6; or

b) a heavy chain polypeptide comprising the sequence set forth in SEQ ID NO:8 and a light chain polypeptide comprising the sequence set forth in SEQ ID NO:10.

2. The monoclonal antibody or binding fragment of claim 1 , in association with a pharmaceutically acceptable carrier.

3. The monoclonal antibody or binding fragment of claim 1 , wherein said monoclonal antibody or binding fragment is linked to a therapeutic agent.

4. The monoclonal antibody or binding fragment of claim 3 , wherein said therapeutic agent is a radionuclide.

5. The monoclonal antibody or binding fragment of claim 3 , wherein the therapeutic agent is a toxin.

6. The monoclonal antibody or binding fragment of claim 1 , wherein said monoclonal antibody or binding fragment does not generate a detectable human anti-human antibody (HAHA) immune response when administered to a human patient.

7. An assay kit for the detection of Matriptase in mammalian tissues or cells comprising the monoclonal antibody or binding fragment of claim 1 and an indicating means for detecting the binding of the monoclonal antibody or binding fragment with Matriptase when Matriptase is present.

8. The assay kit of claim 7 , wherein the monoclonal antibody is a fully human monoclonal antibody.

9. The assay kit of claim 8 , wherein the antibody is labeled.

10. The assay kit of claim 8 , wherein the antibody is an unlabeled first antibody and the indicating means comprises a labeled second antibody that is an anti-immunoglobulin.

11. The assay kit of claim 8 , wherein the antibody is labeled with a marker selected from the group consisting of a fluorochrome, an enzyme, a radionuclide and a radiopaque material.

12. The monoclonal antibody or binding fragment of claim 1 , wherein said binding fragment is selected from the group consisting of Fab, Fab′, F(ab′) 2 , and Fv.

13. The monoclonal antibody or binding fragment of claim 1 , wherein said monoclonal antibody comprises a heavy chain polypeptide comprising the sequence set forth in SEQ ID NO:4 and a light chain polypeptide comprising the sequence set forth in SEQ ID NO:6.

14. The monoclonal antibody or binding fragment of claim 1 , wherein said monoclonal antibody comprises a heavy chain polypeptide comprising the sequence set forth in SEQ ID NO:8 and a light chain polypeptide comprising the sequence set forth in SEQ ID NO:10.

15. An isolated nucleic acid molecule encoding one of the heavy chain polypeptide or the light chain polypeptide of element a) or b) of claim 1 .

16. A vector comprising the nucleic acid molecule of claim 15 .

17. An isolated host cell comprising the vector of claim 16 .

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 042389 FRAME: 505. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Feb 14, 2018
From: DENDREON PHARMACEUTICALS, INC.
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 046088/0882 →
RELEASE OF SECURITY INTEREST Recorded Jul 5, 2017
From: BARCLAYS BANK PLC
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 043089/0288 →
CHANGE OF NAME Recorded May 3, 2017
From: DENDREON PHARMACEUTICALS, INC.
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 042389/0505 →